Pfizer's attempts to prove Lyrica effective as an epilepsy treatment have delivered mixed results. Just three months ago, the controlled-release formula failed a Phase III trial in adults with epilepsy. But now, the company has unveiled new data showing that Lyrica capsules matched the UCB seizure drug Keppra at reducing a common type of seizures in epilepsy patients.
There's a bumper crop of numbers today as pharma's earnings season winds down. The dominant trends continue--the stronger dollar, generic competition (for branded drugmakers), new copycat products (for generics firms) and lots of expectations-management.
South San Francisco personalized medicine/diagnostics startup Nodality has signed a multi-year collaborative deal with Belgium's UCB Pharma that will initially focus on possible companion diagnostics
Yet another drugmaker has joined the off-label marketing club. UCB agreed to pay $34 million to resolve claims it marketed its epilepsy drug Keppra to treat headaches and pain, uses not approved by
You can't accuse UCB of lacking nerve. The company says it's going to test its rheumatoid arthritis drug Cimzia against Abbott Laboratories' well established Humira treatment. As Reuters reports,
Belgian drugmaker UCB is spending €250 million ($333 million) on a new manufacturing plant in Switzerland to make sure it can keep up with demand for its rheumatoid arthritis and Crohn's disease
UCB could end up paying Cimzia royalties to a U.K. charitable trust. The Mathilda and Terence Kennedy Institute of Rheumatology Trust has sued the Belgian drugmaker for patent infringement in a case
It's a banner day for earnings reports, with Bristol-Myers Squibb posting double-digit increases in sales and profits and AstraZeneca hiking its 2010 earnings forecast. Sanofi-Aventis recorded
Want to take the temperature of the U.K.'s National Institute for Health and Clinical Excellence? Just monitor the drugs they recommend for use by the National Health Service--and those they don't.
GlaxoSmithKline doesn't expect profit margins to slip substantially despite an aggressive drive to diversify into areas such as consumer health and emerging markets, CEO Andrew Witty ( photo ) told